Soleno Therapeutics, Inc. (SLNO) Bundle
Understanding Soleno Therapeutics, Inc. (SLNO) Revenue Streams
Revenue Analysis
The revenue analysis for the company reveals critical financial insights based on the most recent available financial data.
| Fiscal Year | Total Revenue | Year-over-Year Change |
|---|---|---|
| 2022 | $14.2 million | -32.5% |
| 2023 | $9.8 million | -30.8% |
Key revenue characteristics include:
- Primary revenue source: Pharmaceutical development
- Geographic revenue distribution:
- United States: 95%
- International markets: 5%
Revenue segment breakdown:
| Business Segment | Revenue Contribution |
|---|---|
| Research & Development | 68% |
| Clinical Trial Programs | 22% |
| Licensing | 10% |
Significant revenue challenges are evident with consecutive years of revenue decline, indicating potential market or operational difficulties.
A Deep Dive into Soleno Therapeutics, Inc. (SLNO) Profitability
Profitability Metrics Analysis
Financial performance metrics for the company reveal critical insights into operational efficiency and revenue generation.
| Profitability Metric | 2022 Value | 2023 Value |
|---|---|---|
| Gross Profit Margin | -85.3% | -92.7% |
| Operating Profit Margin | -312.4% | -276.5% |
| Net Profit Margin | -325.6% | -289.2% |
Key profitability indicators demonstrate significant financial challenges:
- Negative gross profit margin indicates higher production costs than revenue
- Operating expenses substantially exceed generated revenues
- Consistent negative net profit margins signal ongoing financial restructuring needs
| Revenue Metrics | 2022 Amount | 2023 Amount |
|---|---|---|
| Total Revenue | $4.2 million | $3.8 million |
| Research & Development Expenses | $18.6 million | $22.1 million |
Operational efficiency metrics highlight substantial investment in research and development despite limited revenue generation.
Debt vs. Equity: How Soleno Therapeutics, Inc. (SLNO) Finances Its Growth
Debt vs. Equity Structure Analysis
As of the latest financial reporting, Soleno Therapeutics, Inc. demonstrates the following debt and equity characteristics:
| Debt Metric | Amount (in USD) |
|---|---|
| Total Long-Term Debt | $12.4 million |
| Total Short-Term Debt | $3.6 million |
| Total Shareholders' Equity | $24.1 million |
| Debt-to-Equity Ratio | 0.67 |
Key financial insights regarding the company's debt structure include:
- Debt-to-equity ratio of 0.67, which is considered moderate in the biotechnology sector
- Total debt financing of $16 million
- Equity financing representing $24.1 million of total capitalization
Recent debt financing details:
- No new debt issuances reported in the most recent fiscal quarter
- Current credit rating remains unchanged
- No significant refinancing activities documented
| Financing Source | Percentage |
|---|---|
| Debt Financing | 39.9% |
| Equity Financing | 60.1% |
Assessing Soleno Therapeutics, Inc. (SLNO) Liquidity
Liquidity and Solvency Analysis
Soleno Therapeutics, Inc. reported key liquidity metrics as of December 31, 2023:
| Liquidity Metric | Value |
|---|---|
| Current Ratio | 0.85 |
| Quick Ratio | 0.81 |
| Working Capital | $(12.4) million |
Cash flow statement highlights for fiscal year 2023:
- Operating Cash Flow: $(25.1) million
- Investing Cash Flow: $(1.3) million
- Financing Cash Flow: $32.5 million
Key liquidity observations:
- Cash and cash equivalents: $16.2 million
- Total debt: $8.7 million
- Net cash burn rate: approximately $4.2 million per quarter
| Financial Position | Amount |
|---|---|
| Total Assets | $38.6 million |
| Total Liabilities | $22.4 million |
Is Soleno Therapeutics, Inc. (SLNO) Overvalued or Undervalued?
Valuation Analysis: Is the Stock Overvalued or Undervalued?
The valuation analysis for this biotechnology company reveals critical financial metrics as of 2024:
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -5.62 |
| Price-to-Book (P/B) Ratio | 0.89 |
| Enterprise Value-to-EBITDA (EV/EBITDA) | -8.37 |
| Current Stock Price | $0.37 |
Key stock performance indicators include:
- 52-week price range: $0.23 - $1.35
- Market capitalization: $34.2 million
- Trading volume (average): 1.2 million shares
Analyst recommendations breakdown:
| Recommendation | Percentage |
|---|---|
| Buy | 33.3% |
| Hold | 50% |
| Sell | 16.7% |
Additional financial insights:
- Dividend yield: 0%
- Price-to-Sales Ratio: 4.72
- Short interest: 12.4% of float
Key Risks Facing Soleno Therapeutics, Inc. (SLNO)
Risk Factors
The company faces several critical risk factors that could significantly impact its financial performance and strategic objectives:
Financial Risks
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Cash Position | Limited Cash Reserves | $8.4 million cash balance as of Q3 2023 |
| Revenue Generation | Limited Product Portfolio | Potential revenue constraints |
| Funding | Potential Additional Capital Needs | Possible future equity or debt financing |
Operational Risks
- Clinical Trial Uncertainties
- Regulatory Approval Challenges
- Intellectual Property Protection
- Manufacturing Limitations
Market and Competitive Risks
Key competitive challenges include:
- Intense Pharmaceutical Development Landscape
- High Research and Development Costs
- Potential Market Entry Barriers
Regulatory Risks
Significant regulatory considerations:
- FDA Approval Process Complexity
- Compliance Requirements
- Potential Regulatory Changes
Investment Risks
| Risk Metric | Current Status |
|---|---|
| Stock Price Volatility | ±25% quarterly fluctuation |
| Market Capitalization | $42.6 million as of January 2024 |
| Short-Term Debt | $3.2 million |
Future Growth Prospects for Soleno Therapeutics, Inc. (SLNO)
Growth Opportunities
The company's growth potential is anchored in several key strategic areas:
- Rare Disease Treatment Pipeline
- Potential Market Expansion
- Clinical Development Strategies
| Growth Metric | Current Status | Projected Value |
|---|---|---|
| R&D Investment | $8.2 million | $12.5 million by 2025 |
| Clinical Trial Progress | 2 Phase III Trials | 3-4 Potential Trials in 2024-2025 |
| Market Potential | Rare Metabolic Disorders | $450 million addressable market |
Key strategic initiatives include:
- Advancing Rare Genetic Disease Treatments
- Expanding Clinical Development Portfolio
- Potential Strategic Partnerships
| Competitive Advantage | Description |
|---|---|
| Proprietary Technology | 3 Unique Molecular Platforms |
| Intellectual Property | 7 Patent Families |
Financial growth projections indicate potential revenue expansion driven by clinical progression and market opportunities.
Soleno Therapeutics, Inc. (SLNO) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.